NASDAQ · INAB
Healthcare · Biotechnology
$1.10
Down-$0.08 (-6.78%)
Updated Aug 15, 2026, 9:45 AM
SID Score
2.8/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 21 trading sessions · Daily adjusted prices
INAB closed at $1.10 after 21 trading sessions, down 17.29% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 14, 2026 | $1.19 | $1.1998 | $1.10 | $1.10 | 56.01K |
| Aug 13, 2026 | $0.9994 | $1.19 | $0.94 | $1.18 | 375.67K |
| Aug 12, 2026 | $1.07 | $1.0749 | $0.88 | $0.9985 | 90.56K |
| Aug 11, 2026 | $1.00 | $1.05 | $0.9802 | $1.05 | 57.92K |
| Aug 10, 2026 | $0.98 | $1.0099 | $0.9579 | $0.9759 | 67.43K |
| Aug 7, 2026 | $0.97 | $0.98 | $0.9507 | $0.9786 | 36.58K |
| Aug 6, 2026 | $0.9888 | $0.9888 | $0.90 | $0.9699 | 76.87K |
| Aug 5, 2026 | $1.00 | $1.0001 | $0.94 | $0.9888 | 39.88K |
| Aug 4, 2026 | $0.99 | $0.991 | $0.94 | $0.9601 | 37.74K |
| Aug 3, 2026 | $1.08 | $1.08 | $0.94 | $0.96 | 152.09K |
| Jul 31, 2026 | $1.08 | $1.08 | $1.01 | $1.035 | 57.63K |
| Jul 30, 2026 | $1.0554 | $1.08 | $0.9604 | $1.08 | 82.63K |
| Jul 29, 2026 | $1.115 | $1.1262 | $1.055 | $1.07 | 58.33K |
| Jul 28, 2026 | $1.1792 | $1.1792 | $1.10 | $1.11 | 81.75K |
| Jul 27, 2026 | $1.23 | $1.24 | $1.18 | $1.19 | 30.62K |
| Jul 24, 2026 | $1.20 | $1.2422 | $1.195 | $1.20 | 30.21K |
| Jul 23, 2026 | $1.22 | $1.22 | $1.19 | $1.19 | 34.19K |
| Jul 22, 2026 | $1.2496 | $1.2496 | $1.225 | $1.23 | 24.84K |
| Jul 21, 2026 | $1.2205 | $1.25 | $1.2205 | $1.24 | 38.74K |
| Jul 20, 2026 | $1.32 | $1.33 | $1.23 | $1.26 | 54.6K |
| Jul 17, 2026 | $1.35 | $1.37 | $1.31 | $1.33 | 65.5K |
The latest Smart Investors Daily articles mentioning INAB.
INAB research
Company profile and research snapshot.
IN8bio Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of gamma-delta T cell product candidates for solid and liquid tumors, by employing allogeneic, autologous, and genetically modified gamma-delta T cells. Its product candidates include INB-400, for the treatment of newly diagnosed glioblastoma, or GBM, INB-100 for the treatment of patients with high-risk leukemias undergoing hematopoietic stem cell transplantation, and other product candidates such as INB-200, INB-300, and INB-500.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Mar 13, 2026 | HC Wainwright & Co. | Buy | — |
| Mar 14, 2025 | HC Wainwright & Co. | Buy | — |
| Feb 12, 2025 | HC Wainwright & Co. | Buy | — |
| Feb 11, 2025 | Jones Trading | Buy | — |
| Nov 26, 2024 | HC Wainwright & Co. | Buy | — |
No generated briefing is available yet.
Benzinga · Aug 6, 2026
IN8bio (NASDAQ:INAB) reported quarterly losses of $(0.25) per share which beat the analyst consensus estimate of $(0.37) by 32.43 percent. This is a 79.84 percent increase over losses of $(1.24) per share from the same
Benzinga · Jul 9, 2026
First peer-reviewed publication of chemotherapy-resistant gamma-delta T cells (DeltEx Drug Resistant Immunotherapy or DRI) clinical results in newly diagnosed glioblastoma Repeat-dose patients achieved median
Benzinga · Mar 13, 2026
HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates IN8bio (NASDAQ:INAB) with a Buy and maintains $6 price target.
Benzinga · Mar 12, 2026
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning INAB.
